Artelo Biosciences Highlights Strong Partnering Outlook For ART27.13 After Positive Interim Phase 2 CAReS Results

Artelo Biosciences, Inc., a clinical-stage pharmaceutical company developing therapies that modulate lipid-signaling pathways for cancer, pain, dermatologic, and neurological conditions, has confirmed its strong position to secure a development partner for ART27.13 following encouraging clinical results.

The company recently announced positive interim findings from its Phase 2 CAReS trial evaluating ART27.13 in patients with cancer anorexia-cachexia syndrome (CACS), a condition that affects up to 80% of people living with cancer and remains one of the leading causes of cancer-related death. Currently, there are no FDA-approved treatments for CACS. The interim data showed meaningful improvements in weight, lean body mass, and activity levels in patients treated with ART27.13, highlighting the therapy’s potential to address a major unmet medical need.

Gregory D. Gorgas, President and CEO of Artelo, stated, “This morning’s interim results highlight the potential of ART27.13 to become an FDA and internationally approved therapy for cancer anorexia-cachexia syndrome, an underserved, multi-billion-dollar potential market. Based on strong interest from multiple pharmaceutical companies, and given the strength of our newly released data, our immediate strategy is to secure a development partner to efficiently advance ART27.13 through registrational trials. We plan to provide further updates as soon as practical.”

The promising trial results have attracted interest from multiple pharmaceutical companies that were awaiting the CAReS data. Artelo has stated that, given the strength of the clinical profile and the ongoing discussions with potential partners, it does not plan to internally fund a Phase 3 trial of ART27.13. Instead, the company views a licensing transaction as the most value-enhancing strategy for its shareholders.